A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2020 and analyzes trends in funding since 2005.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.
TAG's annual Report on Tuberculosis Research Funding Trends tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects. The…
Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017. This marks the second year in a row that funding for TB research and development (R&D) exceeded $700 million.
The world spent $726 million on tuberculosis (TB) research in 2016, marking the first time annual spending has exceeded $700 million since TAG began tracking funding in 2005. Although this figure is $105 million above 2015 levels, it remains woefully inadequate when judged against the innovation gaps holding back the TB response and the ambitious global goals to end the TB epidemic by 2030.
Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose.